SS-31

SS-31, also known as Elamipretide (brand name Bendavia) or MTP-131, is a tetrapeptide belonging to the Szeto-Schiller (SS) family of mitochondria-targeted peptides developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College. The peptide has the sequence D-Arg-Dmt-Lys-Phe-NH₂, where Dmt is 2′,6′-dimethyltyrosine — a modified amino acid that contributes to the peptide's unusual properties.

What makes SS-31 scientifically distinctive is its targeting specificity: the peptide crosses the plasma membrane and selectively concentrates in the inner mitochondrial membrane (IMM), where it binds cardiolipin — a unique phospholipid found almost exclusively in the IMM that is essential for mitochondrial function. This targeted mechanism positions SS-31 as one of the most sophisticated mitochondrial therapeutics in preclinical and clinical research.

Mitochondrial dysfunction is now recognized as a central driver of aging, neurodegenerative disease, heart failure, kidney disease, metabolic syndrome, and numerous other conditions. SS-31's ability to directly address mitochondrial health at the cardiolipin level has attracted significant pharmaceutical investment, with the company Stealth BioTherapeutics advancing it through clinical trials for several conditions before encountering financial challenges.

In September 2025, elamipretide received FDA accelerated approval for the treatment of Barth syndrome, a rare genetic mitochondrial disease associated with cardiolipin mutations, under the brand name Forzinity. It remains investigational for all other indications, including primary mitochondrial myopathy, heart failure, and kidney disease. Research continues in both academic and commercial settings.

SS-31 acts through a unique and well-characterized mechanism centered on cardiolipin interaction:

• Cardiolipin binding: SS-31 selectively binds cardiolipin (CL), a tetra-acyl phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is essential for organizing the electron transport chain (ETC) complexes into supercomplexes called "respirasomes" that maximize efficiency of ATP production.
• Electron transport chain optimization: By stabilizing cardiolipin and cytochrome c in the proper orientation, SS-31 improves the efficiency of electron transfer along the respiratory chain, enhancing ATP production and reducing electron "leakage" that generates reactive oxygen species (ROS).
• ROS reduction: By improving ETC efficiency, SS-31 dramatically reduces mitochondrial ROS production — a primary driver of oxidative damage to mitochondrial DNA, proteins, and lipids.
• Mitochondrial membrane potential restoration: SS-31 helps maintain the electrochemical gradient across the inner mitochondrial membrane (ΔΨm), which drives ATP synthesis.
• Cytochrome c retention: SS-31 keeps cytochrome c associated with cardiolipin in the inner membrane, reducing the release of cytochrome c that triggers apoptosis. This anti-apoptotic effect is relevant in ischemia-reperfusion injury.
• Cristae remodeling: Research suggests SS-31 can restore the normal cristae architecture of aged or damaged mitochondria, improving respiratory capacity.

SS-31 has demonstrated effects in a wide range of preclinical models and some early human studies:

• Cardiac protection: Extensive animal data and several clinical trials show SS-31 reduces myocardial injury in ischemia-reperfusion (heart attack) scenarios, improves cardiac function in heart failure models, and reduces infarct size.
• Kidney protection: SS-31 has shown nephroprotective effects in models of acute kidney injury, renal ischemia, contrast nephropathy, and age-related kidney decline. Clinical trials for primary mitochondrial myopathy (PMM) also assessed renal biomarkers.
• Skeletal muscle function: Research in aging animal models shows SS-31 improves skeletal muscle mitochondrial function, muscle strength, and exercise capacity — relevant to sarcopenia (age-related muscle loss).
• Neurodegenerative protection: Animal models of Parkinson's, Alzheimer's, and ALS show improved outcomes with SS-31 treatment, consistent with the role of mitochondrial dysfunction in these diseases.
• Metabolic improvements: SS-31 improves glucose metabolism and insulin sensitivity in animal models of obesity and metabolic syndrome.
• Age-related mitochondrial decline: Studies in aged animals demonstrate reversal of age-related mitochondrial dysfunction and improvements in multiple functional parameters — a finding directly relevant to anti-aging applications.

SS-31 has been evaluated in human clinical trials by Stealth BioTherapeutics, providing more human safety data than most research peptides. Key safety findings:

• Injection site reactions: The most commonly reported adverse effects in clinical trials were injection site reactions including pain, erythema, and bruising. These were mostly mild to moderate.
• Generally well-tolerated: Phase I and II trials for heart failure, primary mitochondrial myopathy, and other indications found SS-31 to be generally well-tolerated at therapeutic doses.
• No major organ toxicity: Clinical trials did not identify significant cardiac, hepatic, or renal toxicity at studied doses.
• Theoretical concerns: Long-term effects of sustained mitochondrial enhancement are not fully characterized; potential interactions with mitochondrial regulatory pathways are possible.

The clinical trial history provides meaningful human safety data — an advantage SS-31 has over most research peptides that lack any clinical trial data. However, the trials also did not achieve their primary endpoints in all cases, and optimal dosing for anti-aging applications has not been established.

Disclaimer: SS-31/Elamipretide is not FDA-approved. The following references clinical trial doses for educational purposes.

Clinical trial dosing provides reference points:

• Heart failure trials: 0.005–0.25 mg/kg administered as a 4-hour IV infusion; subcutaneous doses of 4–40 mg per day were also studied
• Primary mitochondrial myopathy (MMPOWER trial): 40 mg/day subcutaneous injection
• Renal trials: IV infusions at various doses around 0.01–0.05 mg/kg/hour

Research community anecdotal protocols for subcutaneous administration generally reference 5–10 mg doses administered 1–3 times per week. These are not validated human therapeutic doses for any indication.

SS-31 has progressed further through formal clinical development than almost any other research peptide, though it has faced setbacks:

• EMBRACE trial (heart failure): A Phase II trial in acute decompensated heart failure demonstrated significant reductions in cardiac biomarkers and showed numerical benefits in clinical outcomes, though primary endpoints were not consistently met.
• MMPOWER trial: A Phase III trial in primary mitochondrial myopathy (a rare genetic disease) did not meet its primary functional endpoint (6-minute walk distance), though secondary endpoints showed some benefit. Stealth BioTherapeutics subsequently faced financial difficulties, delaying further development.
• Barth syndrome approval: Elamipretide received FDA accelerated approval in September 2025 for the treatment of Barth syndrome under the brand name Forzinity, making it the first approved therapy specifically targeting cardiolipin-related mitochondrial dysfunction.
• Age-related research: Studies by the Bhatt group and others at the University of Washington have demonstrated SS-31's ability to reverse age-related mitochondrial dysfunction in animal models — a finding that positions it within anti-aging research despite its pharmaceutical development path targeting acute disease.
• Preclinical breadth: Hundreds of preclinical studies across cardiac, renal, neurological, metabolic, and musculoskeletal disease models demonstrate consistent mitochondrial protective effects.

The clinical trial data makes SS-31 unusual among anti-aging research peptides — there is actual human pharmacokinetic and safety data available. However, the failure of Phase III trials for its primary pharmaceutical indication highlights the gap between preclinical promise and clinical success.